CD4 and neoplasm: DCIL-15 (not rIL-15)-based DC attenuate tumor-associated Treg and induce therapeutic antitumor immunity in an IL-15Rα- or IL-2Rβ-dependent manner that does not require endogenous production of IL-15 or CD4+ T cell “help”